816 cancer-related genes
A broad set of cancer-related genes is assessed for multiple classes of genomic alteration.
Healthcare & LaboratoryOASIS Health / Comprehensive Cancer Genomic Profiling
TUMOR GENOMICS
SENTIS™ Cancer + Discovery
Comprehensive Cancer Genomic Profiling
Genomic information to support consideration of cancer treatment options.
A tumor profiling test that analyses tumor tissue or circulating tumor DNA and organises genomic findings relevant to treatment and clinical-trial discussions.
816 genesTissue or ctDNAIncludes TMB and MSI analysis
04 / 0501
OVERVIEW
About SENTIS™ Cancer + Discovery
Comprehensive genomic profiling analyses many cancer-related genes in one test and organises information about detected alterations, therapies, guidelines and clinical trials.
SENTIS™ Cancer + Discovery Panel accepts tumor tissue or plasma ctDNA and assesses SNVs, indels, copy-number changes, gene fusions, tumor mutational burden and microsatellite instability.
02
FEATURES
Key features
Tissue and ctDNA options
Tumor tissue is accepted, with a plasma circulating-tumor-DNA option available in appropriate circumstances.
Clinically organised reporting
Detected alterations and related clinical information are organised to support the treating physician’s assessment.
03
SPECIFICATION
Test specification
- Test category
- Tumor genomic profiling
- Specimen
- FFPE tissue / fresh tissue / plasma ctDNA
- Genes
- 816
- Alteration types
- SNV / indel / CNV / fusion
- Biomarkers
- TMB / MSI and other reported indicators
- Turnaround
- Approximately 20–25 business days; specimen and analysis status may affect timing
- Access
- Ordered through a medical institution and physician
Specifications and turnaround may vary according to specimen quality, transport, analytical status and the menu offered by the medical institution.
04
DETAILS
Tissue Panel
Analyses tumor tissue collected during surgery or biopsy.
- FFPE or fresh tumor tissue
- Specimen quality and tumor content are assessed
- Analysis may not be possible when tissue is insufficient
ctDNA Panel
A liquid-biopsy option that analyses tumor-derived DNA circulating in blood.
- Blood-based specimen collection
- Low ctDNA levels may prevent detection
- A negative result cannot exclude alterations in the tumor
Report content
Findings are organised in relation to published evidence and clinical information.
- Detected genomic alterations
- Information related to therapies
- Related clinical-trial information
- TMB, MSI and other indicators
05
PROCESS
Testing process
- 01
Clinical consultation
The purpose of testing, clinical status and specimen availability are reviewed.
- 02
Information and consent
Test limitations and possible secondary findings are explained.
- 03
Specimen preparation
Tissue or blood is prepared under the specified conditions.
- 04
Quality review and analysis
Nucleic-acid extraction, quality review, sequencing and bioinformatics are performed.
- 05
Clinical review
The treating physician considers the report alongside the complete clinical context.
06
FAQ
Frequently asked questions
QWill every detected alteration have an available treatment?＋
ANo. A related therapy may not exist, may not be approved locally or may not be suitable for the individual’s clinical condition.
QDoes a negative blood result mean that the tumor has no genomic alterations?＋
ANo. ctDNA levels vary by cancer type, disease stage and treatment status. An alteration may be present in tissue even when it is not detected in plasma.
Important information
Treatment decisions cannot be made from this test alone. The treating physician must consider regulatory approval, insurance coverage, clinical condition and other relevant information.